The CorPath GRX robotic surgical device from Corindus Vascular Robotics.
Corindus Vascular Roboticshas won clearance from Japan’s Pharmaceutical and Medical Device Agency for its CorPath GRX robotic surgical device.
The CorPath GRX vascular robotics platform is designed to assist cardiologists in performing percutaneous coronary interventions (PCI) procedures, including angioplasty and stent placement. Japan is one of the largest markets in the world for PCIs, according to the announcement, with approximately 250,000PCI procedures performed annually.
“I look forward to offering CorPath GRX to my patients during PCI, especially in complex procedures where precision and procedural control are extremely valuable. We are pleased to be one of the first Asia-Pacific countries to adopt this new and innovative technology,” Dr. Takafumi Ueno of Japan’s Kurume University Hospita said in a press release.
去年二月，科林德斯inked a Japanese distribution deal为其CorPath GRX设备that included a $2 million advance and provision for 12 of the robot-assisted surgery platforms.
“There is strong demand for robotic-assisted intervention from key opinion leaders and the broad clinical community in Japan. PMDA approval of CorPath GRX in Japan represents a significant step in our ongoing effort to bring cutting-edge vascular robotics to global markets,” said Corindus president & CEO Mark Toland. “We believe robotics has the potential to enhance patient care in Japan by offering the benefits of robotic precision and advanced tools for physicians to perform these life-saving procedures.”
总部位于马萨诸塞州沃尔瑟姆的Corindus血管机器人表示，该地区正在为该地区的机器人经皮冠状动脉干预程序寻求报销覆盖范围，并计划对该设备进行市场后研究。
上个月，Corindus看到机器人手术平台制造商在2018年第一季度的收入结果中错过了对华尔街的销售期望之后的股票下跌。2018年3月，Corindus血管筹集了2500万美元to support global commercialization of its CorPath GRX robotic surgical system.
It also that month收到510（k）通关来自美国食品药品监督管理局（FDA）的首个为其CORPATH GRX平台设计的自动机器人运动。专有软件功能称为“缩回旋转”（ROR）（ROR）是Corpath GRX平台Techniq系列中的第一个自动化机器人运动。它允许操作员通过在操纵杆缩回时自动旋转导向线来快速导航到靶向病变。
Filed Under:The Robot Report,Robotics • robotic grippers • end effectors
Tell Us What You Think!